Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market by Drug Class and Route of Administration - Global Industry Analysis & Forecast to 2027
Published On : August 2019 Pages : 152 Category: Pharmaceuticals Report Code : HC085103
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market By Drug Class (Alpha-1 proteinase inhibitor, Bronchodilators, Steroids, Antibiotics), By Route of Administration (Oral, Injection, Inhalation) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Alpha-1 antitrypsin is one of the protein synthesized in the liver and travels through the blood protecting the organs of the body from the harmful effects of other proteins. Alpha-1 Antitrypsin Deficiency (AATA), also called genetic Chronic Obstructive Pulmonary Disease (COPD), refers to a genetic condition resulting in increased susceptibility for lung and related disease. Every individual receives two copies of alpha-1 antitrypsin genes, one form each parent. Individuals that receive one normal and one damaged or two damaged copies of alpha-1 antitrypsin genes have considered to have alpha-1 antitrypsin deficiency.
Drivers and Restraints
The rising number of AATD cases has prompted the development of AATD enlargement treatment advertise in North America and is probably going to support the development of the market in this district through the figure time frame. There have been critical enhancements in AATD demonstrative methods utilized in numerous pieces of Asia Pacific. Moreover, the accentuation on AATD by the administration in Asia Pacific is probably going to empower development in the territorial market in the imminent years. In spite of North America's strength, Asia Pacific will develop as the quickest developing district in the conjecture time frame.
Regional Insights
The rising number of AATD cases in North America is fueling the demand for AATD augmentation therapy in this region.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Grifols S.A.
- CSL Limited
- Baxter
- Kamada Ltd.
- Takeda Pharmaceutical Company Limited
- Abeona Therapeutics Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Drug Class, Estimates and Forecast, 2017-2027 ($Million)
o Alpha-1 proteinase inhibitor
o Bronchodilators
o Steroids
o Antibiotics
· Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Route of Administration, Estimates and Forecast, 2017-2027 ($Million)
o Oral
o Injection
o Inhalation
· Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Grifols S.A.
o CSL Limited
o Baxter
o Kamada Ltd.
o Takeda Pharmaceutical Company Limited
o Abeona Therapeutics Inc.
· Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Country
o U.S. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Europe
§ Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Country
o Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Rest of Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Asia-Pacific
§ Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Country
o China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Rest of Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o South America
§ South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Columbia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Rest of South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Middle East and Africa
§ Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o UAE Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Nigeria Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
o Rest of MEA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Drug Class
5.1. Introduction
5.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Market Share by Drug Class (2017-2027)
5.2.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Revenue Share by Drug Class (2017-2027)
5.3. Alpha-1 proteinase inhibitor
5.3.1. Global Alpha-1 proteinase inhibitor Revenue and Growth Rate (2017-2027)
5.4. Bronchodilators
5.4.1. Global Bronchodilators Revenue and Growth Rate (2017-2027)
5.5. Steroids
5.5.1. Global Steroids Revenue and Growth Rate (2017-2027)
5.6. Antibiotics
5.6.1. Global Antibiotics Revenue and Growth Rate (2017-2027)
6. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Route Of Administration
6.1. Introduction
6.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Market Share by Route Of Administration (2017-2027)
6.2.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Revenue Share by Route Of Administration (2017-2027)
6.3. Oral
6.3.1. Global Oral Revenue and Growth Rate (2017-2027)
6.4. Injection
6.4.1. Global Injection Revenue and Growth Rate (2017-2027)
6.5. Inhalation
6.5.1. Global Inhalation Revenue and Growth Rate (2017-2027)
7. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Region
7.1. Introduction
7.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Market Share by Regions
7.2.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Regions (2017-2027)
7.3. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Countries
7.3.1. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2017-2027)
7.3.2. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Countries
7.4.1. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2017-2027)
7.4.2. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Countries
7.5.1. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Countries
7.6.1. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2017-2027)
7.6.2. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Countries
7.7.1. Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Grifols S.A.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. CSL Limited
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Baxter
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Kamada Ltd.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Takeda Pharmaceutical Company Limited
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Abeona Therapeutics Inc.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
9. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast by Regions (2017-2027)
9.2.1. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.1.1. United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.1.2. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.1.3. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.2. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.2.1. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.2.2. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.2.3. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.2.4. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.2.5. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.3. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.3.1. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.3.2. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.3.3. Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.3.4. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.4. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.4.1. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.4.2. Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.4.3. Columbia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.4.4. Rest of South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.5. Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.5.3. Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.5.4. Nigeria Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.5.5. South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.5.6. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2017-2027)
9.3. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast by Drug Class (2017-2027)
9.3.1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Drug Class (2017-2027)
9.3.2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share Forecast by Drug Class (2017-2027)
9.4. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast by Route Of Administration (2017-2027)
9.4.1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Route Of Administration (2017-2027)
9.4.2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share Forecast by Route Of Administration (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Revenue Share by Drug Class (2017-2018)
Figure Global Alpha-1 proteinase inhibitor Revenue and Growth Rate (2017-2018)
Figure Global Bronchodilators Revenue and Growth Rate (2017-2018)
Figure Global Steroids Revenue and Growth Rate (2017-2018)
Figure Global Antibiotics Revenue and Growth Rate (2017-2018)
Table Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Revenue Share by Route Of Administration (2017-2018)
Figure Global Oral Revenue and Growth Rate (2017-2018)
Figure Global Injection Revenue and Growth Rate (2017-2018)
Figure Global Inhalation Revenue and Growth Rate (2017-2018)
Table Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Regions (2017-2018)
Figure North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2017-2018)
Figure North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Countries (2017-2018)
Figure North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) by Countries (2017-2018)
Figure United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2017-2018)
Figure Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Countries (2017-2018)
Figure Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) by Countries (2017-2018)
Figure Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Rest of Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Countries (2017-2018)
Figure Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) by Countries (2017-2018)
Figure China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2017-2018)
Figure South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Countries (2017-2018)
Figure South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Columbia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Rest of South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Countries (2017-2018)
Figure Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure United Arab Emirates Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Nigeria Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2017-2018)
Table Grifols S.A. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Financial Overview
Table CSL Limited Alpha-1 Antitrypsin Deficiency Augmentation Therapy Financial Overview
Table Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Financial Overview
Table Kamada Ltd. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Financial Overview
Table Takeda Pharmaceutical Company Limited Alpha-1 Antitrypsin Deficiency Augmentation Therapy Financial Overview
Table Abeona Therapeutics Inc. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Financial Overview
Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Millions USD) and Growth Rate (2018-2025)
Table Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast by Regions (2018-2025)
Figure North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Rest of Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Columbia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Rest of South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure United Arab Emirates Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Nigeria Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (2018-2025)
Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Drug Class (2018-2025)
Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share Forecast by Drug Class (2018-2025)
Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Drug Class (2018-2025)
Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Route Of Administration (2018-2025)
Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share Forecast by Route Of Administration (2018-2025)
Figure Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Route Of Administration (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|